Since Fetuin-A is one of the several potential vascular calcification inhibitors in chronic kidney disease patients [25], an increase in its levels may be beneficial, as it was associated with a significant reduction in the all-cause mortality of uremic patients [26]. Here, AHSG is linked to chronic kidney disease.